Literature DB >> 2450307

Ciclosporin A prevents P2 T cell line-mediated experimental autoimmune neuritis (AT-EAN) in rat.

H P Hartung1, B Schäfer, W Fierz, K Heininger, K V Toyka.   

Abstract

Adoptive transfer experimental autoimmune neuritis (AT-EAN) produced in Lewis rats by injection of P2-reactive T lymphocyte line cells offers the unique possibility to study the exclusive contribution of cell-mediated immune responses to the pathogenesis of autoimmune disease of the peripheral nervous system (PNS). It further lends itself to the evaluation of novel therapeutic approaches that may bear relevance to the human acute Guillain-Barré syndrome. The effects of the immunosuppressive agent ciclosporin A on the clinical, electrophysiological and morphological expression of AT-EAN were examined. We found that ciclosporin A suppressed development of the disease. In view of the known actions of ciclosporin A on T cells, these results indicate the requirement of activation and clonal proliferation of T lymphocytes to produce myelin damage in autoimmune diseases of the PNS.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2450307     DOI: 10.1016/0304-3940(87)90240-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Demyelination of retinal myelinated nerve fibers in Behcet's disease.

Authors:  P S Chavis; K F Tabbara
Journal:  Doc Ophthalmol       Date:  1998       Impact factor: 2.379

Review 2.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

3.  The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally.

Authors:  Ramona Aronovich; Aviva Katzav; Joab Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 5.  An update in guillain-barré syndrome.

Authors:  J B Winer
Journal:  Autoimmune Dis       Date:  2014-01-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.